Markku Jalkanen
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Markku Jalkanen (born 1954) is a scientist, biotech entrepreneur and businessman from Turku, Finland. He is the CEO of Faron Pharmaceuticals, a Finnish biopharmaceutical company listed on London's Alternative Investment Market. Jalkanen was the founding CEO and President of Biotie Therapies, the first publicly traded biotech-company in Finland.[1] He is an advisor for the Finnish life-science fund, Inveni Capital.[2]
Education and career
Jalkanen obtained a master's degree in Medical Biochemistry from the University of Kuopio, a PhD in Medical Biochemistry from the University of Turku and completed his post-doctoral training at Stanford University.[1]
Jalkanen has received awards for his scientific research and business achievements: The Anders Jahre Medical Prize for Younger Researchers in 1993,[3] The Developer of Turku Award of 1993,[4] The 1994 Academic Publicity Award,[4] Teacher of the Year 1996 of the University of Turku,[4] The Inno-Suomi Award in 1998 for the entrepreneurial industrialization of academic discoveries (BioTie) [5]
Jalkanen pioneered the Finnish biotech development while being the first Director (Professor) of Turku Biotechnology Center within BioCity community in Turku.[6] He has published over 130 peer reviewed scientific publications and has a HIRSCH-index of >45.[4]
References
- ^ a b "Faron Pharmaceutical, Markku Jalkanen".
- ^ "Inveni Capital, team".
- ^ "DUODECIM 1993;109(19):1626, Vuoden 1993 Anders Jahren palkinto Markku Jalkaselle".
- ^ a b c d "Åbo Akademi, Management of Innovations and Entrepreneurship Guestlecture 27.9. 2004 14-15 in Aud III" (PDF).
- ^ "Tiede 1.1.2004, BioTiellä vielä pitkä marssi".
- ^ "Taloussanomat 23.10.1998, Lupaavat kasvuyritykset vievät ideat tuotteeksi".
| International | |
|---|---|
| National | |
